1.Department of Urology, Yueqing People’s Hospital, Wenzhou 325600, China; 2.Department of Urology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China
ZHENG Rongwei,ZHAO Yihua,HUANG Wei, et al. Clinical characteristics and prognosis of different molecular classification bladder cancer[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2019, 49(10): 760-764.
Abstract：Objective: To analyze the clinical characteristics and prognosis of patients with different molecular classification bladder cancer by taking for example the classification of bladder cancer cell division cycle related factor 3 (CDCA3). Methods: Based on the American Cancer Genome Atlas (TCGA) database, 147 copies of bladder cancer CDCA3 gene expression profiles and related cases were downloaded. The CDCA3 expression levels were ranked from low to high to find the median. The samples were divided as CDCA3 low expression group (74 cases before the median) and CDCA3 high expression group (73 cases after the median). The clinical features and prognosis were compared between different CDCA3 genotype bladder cancer patients, and the mechanism of CDCA3 in the development and progression of bladder cancer was analyzed. Results: The proportion of patients with myometrial invasion, the stage of T stage and N stage, and the proportion of tumor metastasis in CDCA3 high expression group were higher than those in CDCA3 low expression group, and the tumor differentiation degree was lower than that in CDCA3 low expression group with significant difference (P<0.05). The recurrence rate of CDCA3 high expression group was higher than that of CDCA3 low expression group at 1 year and 3 years, with significant difference (P<0.05). The 1-year and 3-year survival rates of the CDCA3 high expression group were lower than those of the CDCA3 low expression group with significant difference (P<0.05). GSEA found that over-expressed CDCA3 bladder cancer cells were enriched with G2M checkpoints, glycolysis, E2F signaling pathway, MYC signaling pathway, MTOR signaling pathway, PTK pathway, PI3K-AKT-mTOR signaling pathway, mitotic spindle, unfolded protein Gene sets such as reaction, cholesterol protein, and spermatogenesis. Conclusion: The lower the CDCA3 gene expression level, the lower the tumor stage, the smaller the risk of tumor metastasis, the higher the degree of differentiation, the better the prognosis, and the lower the recurrence rate and mortality. The role of CDCA3 gene is achieved through the regulation of multiple gene pathways. CDCA3 gene may be a potential biomarker for bladder cancer, which can be evaluated by an analysis of its expression level and prognosis.
